CAT 5571

Drug Profile

CAT 5571

Alternative Names: CAT-5571

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Antifibrotics; Docosahexaenoic acids; Small molecules
  • Mechanism of Action Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 09 Nov 2017 Catabasis Pharmaceuticals plans a phase I trial for Cystic fibrosis in 2H 2018
  • 17 Nov 2016 Catabasis Pharmaceuticals plans a phase I trial for Cystic fibrosis
  • 27 Oct 2016 Positive pharmacodynamics data from preclinical study released by Catabasis Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top